The chemistry of irreversible capture

Reardan, 1985, Antibodies against metal chelates, Nature, 316, 265, 10.1038/316265a0 Stickney, 1991, Bifunctional antibody: a binary radiopharmaceutical delivery system for imaging colorectal carcinoma, Cancer Res., 51, 6650 Love, 1993, How the anti-(metal chelate) antibody CHA255 is specific for the metal ion of its antigen: X-ray structures for two Fab'/hapten complexes with different metals in the chelate, Biochemistry, 32, 10950, 10.1021/bi00092a004 Chmura, 2001, Antibodies with infinite affinity, Proc. Natl. Acad. Sci. U. S. A., 98, 8480, 10.1073/pnas.151260298 Baker, 1961, Potential anticancer agents. LXVI. Non-classical antimetabolites. III. 4-(Iodoacetamido)-salicylic acid, an exo alkylating irreversible inhibitor of glutamic dehydrogenase, J. Am. Chem. Soc., 83, 3713, 10.1021/ja01478a034 Schoellmann, 1963, Direct evidence for the presence of histidine in the active center of chymotrypsin, Biochemistry, 2, 252, 10.1021/bi00902a008 Wofsy, 1962, Affinity labeling-A general method for labeling the active sites of antibody and enzyme molecules, Biochemistry, 1, 1031, 10.1021/bi00912a013 Fry, 1998, Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor, Proc. Natl. Acad. Sci. U. S. A., 95, 12022, 10.1073/pnas.95.20.12022 Yocum, 1979, Mechanism of penicillin action: penicillin and substrate bind covalently to the same active site serine in two bacterial D-alanine carboxypeptidases, Proc. Natl. Acad. Sci. U. S. A., 76, 2730, 10.1073/pnas.76.6.2730 Chmura, 2002, Electrophilic chelating agents for binding of metal chelates to engineered antibodies, J. Control. Release, 78, 249, 10.1016/S0168-3659(01)00485-0 Corneillie, 2004, Converting weak binders into infinite binders, Bioconjug. Chem., 15, 1389, 10.1021/bc049825e Corneillie, 2004, Irreversible engineering of the multielement-binding antibody 2D12.5 and its complementary ligands, Bioconjug. Chem., 15, 1392, 10.1021/bc049824m Corneillie, 2006, Irreversibly binding anti-metal chelate antibodies: artificial receptors for pretargeting, J. Inorg. Biochem., 100, 882, 10.1016/j.jinorgbio.2006.01.004 Butlin, 2006, Antibodies with infinite affinity: origins and applications, Acc. Chem. Res., 39, 780, 10.1021/ar020275e Fersht, 1985, 56 Pollack, 1988, Introduction of nucleophiles and spectroscopic probes into antibody combining sites, Science (Washington, DC), 242, 1038, 10.1126/science.3194752 Salerno, 1993, Covalent modification with concomitant inactivation of the cAMP-dependent protein kinase by affinity labels containing only L-amino acids, J. Biol. Chem., 268, 13043, 10.1016/S0021-9258(19)38616-8 Yan, 1996, Precision targeting of protein kinases—an affinity label that inactivates the cGMP- but not the cAMP-dependent protein kinase, J. Biol. Chem., 271, 1845, 10.1074/jbc.271.4.1845 Levitsky, 2003, Selective inhibition of engineered receptors via proximity-accelerated alkylation, Org. Lett., 5, 693, 10.1021/ol027448k Chen, 2003, Reactivity of functional groups on the protein surface: development of epoxide probes for protein labeling, J. Am. Chem. Soc., 125, 8130, 10.1021/ja034287m Blanca, 2005, Specificities of B cell reactions to drugs. The penicillin model, Toxicology, 209, 181, 10.1016/j.tox.2004.12.018 Nicholas, 1988, Site-directed mutants of a soluble form of penicillin-binding protein 5 from Escherichia coli and their catalytic properties, J. Biol. Chem., 263, 2034, 10.1016/S0021-9258(19)77981-2 Wymann, 1996, Wortmannin inactivates phosphoinositide 3-kinase by covalent modification of Lys-802, a residue involved in the phosphate transfer reaction, Mol. Cell. Biol., 16, 1722, 10.1128/MCB.16.4.1722 Wipf, 2005, Chemistry and biology of wortmannin, Org. Biomol. Chem., 3, 2053, 10.1039/b504418a Norman, 1995, Synthetic studies on the furan ring of wortmannin, Bioorg. Med. Chem. Lett., 5, 1183, 10.1016/0960-894X(95)00191-U Kunz, 1991, Structure-activity relationships for mitomycin C and mitomycin A analogues, J. Med. Chem., 34, 2281, 10.1021/jm00111a051 Boamah, 2007, Mitomycin-DNA adducts induce p53-dependent and p53-independent cell death pathways, ACS Chem. Biol., 2, 399, 10.1021/cb700060t Corneillie, 2003, Crystal structures of two complexes of the rare-Earth-DOTA-binding antibody 2D12.5: ligand generality from a chiral system, J. Am. Chem. Soc., 125, 15039, 10.1021/ja037236y Corneillie, 2003, A rare earth-DOTA-binding antibody: probe properties and binding affinity across the lanthanide series, J. Am. Chem. Soc., 125, 3436, 10.1021/ja029363k Krusemark, 2007, Covalent labelling of fusion proteins in live cells via an engineered receptor–ligand pair, Org. Biomol. Chem., 5, 2201, 10.1039/B705185A Noll, 2001, Covalent capture of a human O(6)-alkylguanine alkyltransferase-DNA complex using N(1),O(6)-ethanoxanthosine, a mechanism-based crosslinker, Nucleic Acids Res., 29, 4025, 10.1093/nar/29.19.4025 Heinis, 2006, Evolving the substrate specificity of O6-alkylguanine-DNA alkyltransferase through loop insertion for applications in molecular imaging, ACS Chem. Biol., 1, 575, 10.1021/cb6003146